当前位置:
X-MOL 学术
›
Nat. Rev. Drug. Disc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Bispecific antibody pipeline moves beyond oncology
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-09-29 , DOI: 10.1038/nrd.2017.187 Asher Mullard
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-09-29 , DOI: 10.1038/nrd.2017.187 Asher Mullard
Bispecific antibody pipeline moves beyond oncology
中文翻译:
双特异性抗体产品线超越了肿瘤学
双特异性抗体产品线超越了肿瘤学
更新日期:2017-10-11
Nature Reviews Drug Discovery, Published online: 29 September 2017; doi:10.1038/nrd.2017.187
The FDA could soon approve the first bispecific antibody for a non-oncology indication, but clinical applications that make full use of the biological opportunity afforded by the nascent modality remain rare.
中文翻译:
双特异性抗体产品线超越了肿瘤学
双特异性抗体产品线超越了肿瘤学
Nature Reviews Drug Discovery,在线发布:2017年9月29日;doi:10.1038 / nrd.2017.187
FDA可能很快会批准首个双特异性抗体用于非肿瘤适应症,但充分利用新生形式提供的生物学机会的临床应用仍然很少。